ダウンロード数: 240
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
39_1227.pdf | 7.19 MB | Adobe PDF | 見る/開く |
タイトル: | Bisbenzylisoquinolineによる腎癌の多剤耐性の克服 |
その他のタイトル: | Circumvention of the multidrug-resistance in renal cancer by bisbenzylisoquinoline |
著者: | 筧, 善行 橋村, 孝幸 吉田, 修 清川, 岳彦 兼松, 明弘 |
著者名の別形: | Kakehi, Yoshiyuki Hashimura, Takayuki Yoshida, Osamu Segawa, Takehiko Kanematsu, Akihiro |
キーワード: | MDR Renal cell carcinoma Bisbenzylisoquinoline |
発行日: | Dec-1993 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 39 |
号: | 12 |
開始ページ: | 1227 |
終了ページ: | 1232 |
抄録: | A bisbenzylisoquinoline alkaloid, cepharanthine, significantly enhanced vinblastine, adriamycin and etoposide sensitivities in P-glycoprotein positive renal cancer cells. However, it did not show any enhancing effect on cisplatin sensitivity. Four patients with metastatic renal cell carcinomas were treated with intraarterial chemotherapy using vinblastine and/or adriamycin in combination with cepharanthine for their metastatic lesions (3 bone and 1 contralateral kidney metastases). A partial response was observed in 1 patient with femoral bone metastasis and a minor response in 1 patient with lumbar bone metastasis, although they were also treated with interferons. No adverse effects associated with cepharanthine were seen except in one patient complaining of redness and burning sense of the skin probably due to its vaso-dilatation effect. |
URI: | http://hdl.handle.net/2433/117996 |
PubMed ID: | 8285174 |
出現コレクション: | Vol.39 No.12 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。